BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/20/2024 3:53:46 AM | Browse: 74 | Download: 309
 |
Received |
|
2024-08-21 06:10 |
|
Peer-Review Started |
|
2024-07-31 10:56 |
|
First Decision by Editorial Office Director |
|
2024-10-25 04:17 |
|
Return for Revision |
|
2024-10-25 04:17 |
|
Revised |
|
2024-10-30 09:49 |
|
Publication Fee Transferred |
|
2024-11-15 14:37 |
|
Second Decision by Editor |
|
2024-11-15 02:37 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-11-15 06:15 |
|
Articles in Press |
|
2024-11-15 06:15 |
|
Edit the Manuscript by Language Editor |
|
2024-11-25 14:36 |
|
Typeset the Manuscript |
|
2024-12-12 06:49 |
|
Publish the Manuscript Online |
|
2024-12-20 03:53 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
CXCR5+CD8+ T cells as immune regulators in HBeAg-positive chronic hepatitis B under interferon-alpha treatment
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhen-Yu Xu, Zhong-Shang Dai, Guo-Zhong Gong and Min Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Changsha Science and Technology Program |
kq2022397 |
| Natural Science Foundation of Hunan Province (Departmental Joint Fund) |
2023JJ60440 |
| Research Program of Health Commission of Hunan Province |
202303088786 |
| Clinical Medical Research Center for Viral Hepatitis of Hunan Province |
2023SK4009 |
| The Scientific Research Program of FuRong Laboratory |
2023SK2108 |
|
| Corresponding Author |
Min Zhang, MD, Institute of Hepatology and Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, No. 139 Renmin Road Central, Changsha 410011, Hunan Province, China. zhangmin001@csu.edu.cn |
| Key Words |
CXCR5; PD-L1; IL-21; Pegylated interferon-alpha; Chronic hepatitis B |
| Core Tip |
This study highlights the pivotal role of CXCR5+CD8+ T cells in chronic hepatitis B (CHB) during pegylated interferon-alpha treatment. Our findings reveal that patients who achieved sustained serologic response exhibited higher baseline and treatment levels of CXCR5+CD8+ T cells, suggesting a connection between CXCR5 expression and IFN-induced antiviral immune responses. This research emphasizes the importance of CXCR5+CD8+ T cells as a potential biomarker for monitoring treatment efficacy in CHB patients. |
| Publish Date |
2024-12-20 03:53 |
| Citation |
Xu ZY, Dai ZS, Gong GZ, Zhang M. CXCR5+CD8+ T cells as immune regulators in HBeAg-positive chronic hepatitis B under interferon-alpha treatment. World J Gastroenterol 2025; 31(3): 99833 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i3/99833.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i3.99833 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
